Health Care / Hospitals
Releases published in the last 30 days. 
Page 3 of 3
- Johnson & Johnson highlights promising first-in-human Erda-iDRS (formerly TAR-210) results in intermediate‑risk non–muscle-invasive bladder cancer
- 3/14/2026 1:51:46 PM
- · Data presented at EAU 2026 show an 89 percent complete response rate in intermediate-risk disease with durable responses observed over 18 months and tolerable safety profile · Erda-iDRS has the potential to be the first targeted treatment for early-stage bladder cancer Johnson & Johnson (NYSE:JNJ) announced results from an open-label, multicenter Phase 1 study …
- « Previous
- 1
- 2
- 3
- Next »